about
Environment and cardiovascular disease: rationale of the Corinthia studyThe effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: A systematic review and meta-analysis.Incessant pericarditis following dual-chamber cardioverter defibrillation device implantation.Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.Consumption of a boiled Greek type of coffee is associated with improved endothelial function: the Ikaria study.Flavonoids in atherosclerosis: an overview of their mechanisms of action.Dual or Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation? A Systematic Review and Meta-Analysis.Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria studyMicroRNAs: Novel diagnostic and prognostic biomarkers in atherosclerosis.Novel biomarkers assessing endothelial dysfunction: role of microRNAs.MicroRNAs: Biomarkers for cardiovascular disease in patients with diabetes mellitus.MicroRNAs in the diagnosis and treatment of unstable angina.MicroRNAs in cardiovascular therapeutics.Statins in heart failure--With preserved and reduced ejection fraction. An update.Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches.The natural history of multifocal atrial rhythms in elderly outpatients: insights from the "Ikaria study".The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment.Real-time three-dimensional echocardiography: never before clinical efficacy looked so picturesque.Basic Mechanisms in Atherosclerosis: The Role of Calcium.Statins in Aortic Stenosis.Atrial Fibrillation: Biomarkers determining prognosis.Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches.Inflammatory cytokines in atherosclerosis: current therapeutic approaches.Established and novel treatment options in acute myocarditis, with or without heart failure.The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk.Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine.Antiplatelet and Anticoagulation Therapy in Structural Heart Disease Interventions Beyond TAVI.Targeting percutaneous cardiovascular interventions at all who will benefit the most: The reality of the Eastern European countries.Western Dietary Pattern Is Associated With Severe Coronary Artery Disease.Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome.Vitamin D serum levels are associated with cardiovascular outcome in coronary artery disease.Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.Favorable effects of concord grape juice on endothelial function and arterial stiffness in healthy smokers.Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure.Cross-sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patients.Long-term fish intake preserves kidney function in elderly individuals: the Ikaria study.Genetic predisposition to left ventricular hypertrophy and the potential involvement of cystatin-C in untreated hypertension.The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.Statins in aortic disease.
P50
Q26741908-5E0E73CF-A78B-47E6-BC7C-4200F61BF22AQ30244977-2379B701-74BE-468B-9AEB-56BF30A006CCQ33167006-F3638608-BB52-48D0-B85D-7A5613CF6239Q33365061-C155A7FA-683A-4CBD-B8DF-67424C2CE9FDQ34333898-8BC8E485-00B7-4DEE-AC9E-BB257AA25F41Q34341836-E447316F-5A7C-4B83-9B22-7F4A32148753Q36041091-1615C022-76F8-48BE-969A-797AA937FFDAQ37598204-7B12E85D-5AC8-450E-96F4-C99B7BE9D56BQ38112763-5A356A0D-30DA-48F2-B463-118DDD8628FFQ38112765-EAA95A6C-6A21-4B44-A70D-AD7B918D454CQ38112767-4320BD66-FA57-489F-9873-AC2ADE4B1A4BQ38112773-10CFA540-9D15-421F-AF31-A629A5D02AD8Q38112774-23E8B10F-54E8-4713-A07F-9D35950636A1Q38136062-811D59EF-A9D3-4282-9B3D-F9B92CCA1500Q38220131-5938EB86-572D-441D-B106-EF35CEF55123Q38449684-13D0E9AD-C2AE-4A24-9846-BBAF96D93968Q38539103-41CE6573-DEF9-4668-8134-0D6BC0047B23Q38543341-5F7EC504-3197-4AFB-8741-0A63E275BF04Q38594032-08CE5D8D-1132-4D9A-A8DB-B958894AA508Q38621736-76434AB8-177E-4B56-822E-A61AC344A1A9Q38658234-4F936C4C-0818-4B66-92D2-98E8F33BFB82Q38672741-8EAE90BF-57F2-42D0-85B3-EC51B68CC3BAQ38722298-7CCC3747-8F21-4AA5-813F-99C7F4F08D54Q38794097-425DA6AA-543F-4D26-A4E7-9EDE332134DDQ38859904-562FCBAB-E09F-48B3-84C7-2AA3D8B7B184Q38869815-0DD1B32F-35F0-4E56-A600-D14BE3AFF3DFQ39047404-F69BBD7F-8B92-4816-800F-463CC363E92DQ39620211-E1FBDF6D-3D1B-4083-B6FB-3792DFD75F59Q40113545-AE7DAD17-4328-4E1F-9281-A01029F010B7Q41573080-9D315AC5-4A76-4E35-81CF-FEF9B3A770BAQ43855545-B6752E9B-B616-40F7-98CF-A75208AEAC9BQ44233571-EE164F4B-75EA-496C-9E81-AFEDEE43186EQ44395349-E55968F1-AB98-45D4-9C72-6BBBF385AFE0Q44500544-31C66100-4635-4873-8CC0-6B58B5A8D4D8Q44850216-8F9A903E-2B80-4528-9877-1475EAAA8A7AQ45267020-ACDC2A75-CABD-44F3-8873-E51335C3FAE0Q45327956-EAB8B877-4C61-414F-BA8B-83465F0A74E1Q46150520-98A44A58-C7C8-45C0-8EFD-1A04C586122FQ46219234-B83DCC17-2D52-45ED-B60E-73A8CBBE227AQ47591642-6716B68E-6C11-4071-A8FD-228D71C73598
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Evangelos Oikonomou
@ast
Evangelos Oikonomou
@en
Evangelos Oikonomou
@es
Evangelos Oikonomou
@nl
Evangelos Oikonomou
@sl
type
label
Evangelos Oikonomou
@ast
Evangelos Oikonomou
@en
Evangelos Oikonomou
@es
Evangelos Oikonomou
@nl
Evangelos Oikonomou
@sl
prefLabel
Evangelos Oikonomou
@ast
Evangelos Oikonomou
@en
Evangelos Oikonomou
@es
Evangelos Oikonomou
@nl
Evangelos Oikonomou
@sl
P106
P1153
36717891800
P21
P31
P496
0000-0001-8079-0599